This is all based on the 1 Dutch trial by Hans Knoop (Kuut et al. 2023, discussed here). A study on COPD patients found the minimal importance difference for the CIS-fatigue scale to be 9.3 points, so bigger than the 8.4 difference found in the CBT trial. The reviewers rated the Kuut 2023 study at high risk of bias because of lack of blinding but this resulted in only 1 downgrading in GRADE hierarchy from high to moderate certainty of evidence.
Curiously, the RCT on hyperbaric oxygen therapy also reported positive effects but here the evidence was downgraded by two levels (from High to Low) 'due to very serious imprecision' even though for some outcomes the 95% confidence intervals do not cross 0.
This all seems to be based on 1 trialon 'People who were still suffering from breathlessness three months after being discharged from hospital with COVID-19-related acute respiratory distress syndrome.'
https://pubmed.ncbi.nlm.nih.gov/37271020/
EDIT: It seems to be the REGAIN trial that we has was discussed here:
https://www.s4me.info/threads/clini...9-condition-regain-study-2024-mcgregor.37174/
This compares 2 forms of exercise, so provides no evidence that exercise is helpful or not.
I'm also curious how they rated the synbiotic study (thread here) as lower quality of evidence. Not that I believe it has any value in the treatment of LC (the authors didn't report any meaningful data and the LC classifications were nonsense), but it was at least a double blind placebo controlled trial with a "positive outcome".
Last edited: